JCJudit Castillo-Armengol

Judit Castillo-Armengol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Judit Castillo-Armengol has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia

    by Judit Castillo‑Armengol, Flavia Marzetta, Ana Rodriguez Sanchez-Archidona, Christian Fledelius, Mark Evans, Alison McNeilly, Rory J. McCrimmon, Mark Ibberson, Bernard Thorens

  • Open Access

    Disrupted hypothalamic transcriptomics and proteomics in a mouse model of type 2 diabetes exposed to recurrent hypoglycaemia

    by Judit Castillo-Armengol, Flavia Marzetta, Ana Rodriguez Sanchez-Archidona, Christian Fledelius, Mark Evans, Alison McNeilly, Rory J. McCrimmon, Mark Ibberson, Bernard Thorens

    Aims/hypothesis: Repeated exposures to insulin-induced hypoglycaemia in people with diabetes progressively impairs the counterregulatory response (CRR) that restores normoglycaemia. This defect is characterised by reduced secretion of glucagon and other counterregulatory hormones. Evidence indicates that glucose-responsive neurons located in the hypothalamus orchestrate the CRR. Here, we aimed to identify the changes in hypothalamic gene and protein expression that underlie impaired CRR in a mouse model of defective CRR. Methods: High-fat-diet fed and low-dose streptozocin-treated C57BL/6N mice were exposed to one (acute hypoglycaemia [AH]) or multiple (recurrent hypoglycaemia [RH]) insulin-induced hypoglycaemic episodes and plasma glucagon levels were measured. Single-nuclei RNA-seq (snRNA-seq) data were obtained from the hypothalamus and cortex of mice exposed to AH and RH. Proteomic data were obtained from hypothalamic synaptosomal fractions. Results: The final insulin injection resulted in similar plasma glucose levels in the RH group and AH groups, but glucagon secretion was significantly lower in the RH group (AH: 94.5±9.2 ng/l [n=33]; RH: 59.0±4.8 ng/l [n=37]; pAvp, Pmch and Pcsk1n, and the most overexpressed gene was Kcnq1ot1, as compared with AH-exposed mice. Gene ontology analysis of differentially expressed genes (DEGs) indicated a coordinated decrease in many oxidative phosphorylation genes and reduced expression of vacuolar H+- and Na+/K+-ATPases; these observations were in large part confirmed in the proteomic analysis of synaptosomal fractions. Compared with AH-exposed mice, oligodendrocytes from RH-exposed mice had major changes in gene expression that suggested reduced myelin formation. In astrocytes from RH-exposed mice, DEGs indicated reduced capacity for neurotransmitters scavenging in tripartite synapses as compared with astrocytes from AH-exposed mice. In addition, in neurons and astrocytes, multiple changes in gene expression suggested increased amyloid beta (Aβ) production and stability. The snRNA-seq analysis of the cortex showed that the adaptation to RH involved different biological processes from those seen in the hypothalamus. Conclusions/interpretation: The present study provides a model of defective counterregulation in a mouse model of type 2 diabetes. It shows that repeated hypoglycaemic episodes induce multiple defects affecting all hypothalamic cell types and their interactions, indicative of impaired neuronal network signalling and dysegulated hypoglycaemia sensing, and displaying features of neurodegenerative diseases. It also shows that repeated hypoglycaemia leads to specific molecular adaptation in the hypothalamus when compared with the cortex. Data availability: The transcriptomic dataset is available via the GEO (http://www.ncbi.nlm.nih.gov/geo/), using the accession no. GSE226277. The proteomic dataset is available via the ProteomeXchange data repository (http://www.proteomexchange.org), using the accession no. PXD040183. Graphical


  • Open Access

    Supplementary Data from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

  • Open Access

    Data from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

    Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells.Significance:These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.

  • Open Access

    Supplementary Tables from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

    Supplementary Tables. Supplementary Table 1. Target sequences for guide RNA used to create KO stable cell lines with CRISP/Cas9 technology, Supplementary Table 2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) regulated genes (human), Supplementary Table 3. Primers used for qPCR Analysis of Senescence genes (human), Supplementary Table 4. Primers used for qPCR Analysis of housekeeping genes (human), Supplementary Table 5. Primers used for FLCN mutagenesis

  • Open Access

    Supplementary Tables from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

    Supplementary Tables. Supplementary Table 1. Target sequences for guide RNA used to create KO stable cell lines with CRISP/Cas9 technology, Supplementary Table 2. Primers used for qPCR Analysis of Transcription Factor EB (TFEB) regulated genes (human), Supplementary Table 3. Primers used for qPCR Analysis of Senescence genes (human), Supplementary Table 4. Primers used for qPCR Analysis of housekeeping genes (human), Supplementary Table 5. Primers used for FLCN mutagenesis

  • Open Access

    Supplementary Data from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

  • Open Access

    Data from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

    Cyclin-dependent kinase 4 (CDK4) is well-known for its role in regulating the cell cycle, however, its role in cancer metabolism, especially mTOR signaling, is undefined. In this study, we established a connection between CDK4 and lysosomes, an emerging metabolic organelle crucial for mTORC1 activation. On the one hand, CDK4 phosphorylated the tumor suppressor folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids. On the other hand, CDK4 directly regulated lysosomal function and was essential for lysosomal degradation, ultimately regulating mTORC1 activity. Pharmacologic inhibition or genetic inactivation of CDK4, other than retaining FLCN at the lysosomal surface, led to the accumulation of undigested material inside lysosomes, which impaired the autophagic flux and induced cancer cell senescence in vitro and in xenograft models. Importantly, the use of CDK4 inhibitors in therapy is known to cause senescence but not cell death. To overcome this phenomenon and based on our findings, we increased the autophagic flux in cancer cells by using an AMPK activator in combination with a CDK4 inhibitor. The cotreatment induced autophagy (AMPK activation) and impaired lysosomal function (CDK4 inhibition), resulting in cell death and tumor regression. Altogether, we uncovered a previously unknown role for CDK4 in lysosomal biology and propose a novel therapeutic strategy to target cancer cells.Significance:These findings uncover a novel function of CDK4 in lysosomal biology, which promotes cancer progression by activating mTORC1; targeting this function offers a new therapeutic strategy for cancer treatment.

  • Open Access

    Supplementary Figures with Figure legends. from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

    Supplementary Figures and Supplementary Figure legends. Supplementary Fig. 1.- CDK4 inhibition or depletion decreases mTORC1 activity in several cancer cell lines, Supplementary Fig. 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-independent, Supplementary Fig. 3.- CDK4 phosphorylates FLCN, Supplementary Fig. 4.- CDK4 regulates mTORC1 activity through phosphorylating FLCN, Supplementary Fig. 5.- CDK4 inhibition or depletion increases lysosomal mass, Supplementary Fig. 6.- Hematoxylin and eosin staining and gene expression analysis of tumors from mice treated with or without LY2835219, Supplementary Fig. 7.- In vitro cell death analysis and in vivo electron microscopy analysis of tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 with LY2835219

  • Open Access

    Supplementary Figures with Figure legends. from CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival

    by Laia Martínez-Carreres, Julien Puyal, Lucía C. Leal-Esteban, Meritxell Orpinell, Judit Castillo-Armengol, Albert Giralt, Oleksandr Dergai, Catherine Moret, Valentin Barquissau, Anita Nasrallah, et al.

    Supplementary Figures and Supplementary Figure legends. Supplementary Fig. 1.- CDK4 inhibition or depletion decreases mTORC1 activity in several cancer cell lines, Supplementary Fig. 2.- CDK4 effects on mTORC1 are α-ketoglutarate and E2F1-independent, Supplementary Fig. 3.- CDK4 phosphorylates FLCN, Supplementary Fig. 4.- CDK4 regulates mTORC1 activity through phosphorylating FLCN, Supplementary Fig. 5.- CDK4 inhibition or depletion increases lysosomal mass, Supplementary Fig. 6.- Hematoxylin and eosin staining and gene expression analysis of tumors from mice treated with or without LY2835219, Supplementary Fig. 7.- In vitro cell death analysis and in vivo electron microscopy analysis of tumors treated with DMSO, LY2835219, A769662 and the combination of A769662 with LY2835219